416 related articles for article (PubMed ID: 23314920)
1. Plasminogen activator inhibitor-1 in kidney pathology (Review).
Małgorzewicz S; Skrzypczak-Jankun E; Jankun J
Int J Mol Med; 2013 Mar; 31(3):503-10. PubMed ID: 23314920
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 and diabetic nephropathy.
Lee HB; Ha H
Nephrology (Carlton); 2005 Oct; 10 Suppl():S11-3. PubMed ID: 16174279
[TBL] [Abstract][Full Text] [Related]
4. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
6. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.
Maquerlot F; Galiacy S; Malo M; Guignabert C; Lawrence DA; d'Ortho MP; Barlovatz-Meimon G
Am J Pathol; 2006 Nov; 169(5):1624-32. PubMed ID: 17071586
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.
Rerolle JP; Hertig A; Nguyen G; Sraer JD; Rondeau EP
Kidney Int; 2000 Nov; 58(5):1841-50. PubMed ID: 11044203
[TBL] [Abstract][Full Text] [Related]
8. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.
Sandra D; Radha M; Harishkumar M; Yuichi N; Sayuri O; Masugi M
Phytomedicine; 2010 Jan; 17(1):42-6. PubMed ID: 19640694
[TBL] [Abstract][Full Text] [Related]
10. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
13. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
14. Confluence switch signaling regulates ECM composition and the plasmin proteolytic cascade in keratinocytes.
Botta A; Delteil F; Mettouchi A; Vieira A; Estrach S; Négroni L; Stefani C; Lemichez E; Meneguzzi G; Gagnoux-Palacios L
J Cell Sci; 2012 Sep; 125(Pt 18):4241-52. PubMed ID: 22641690
[TBL] [Abstract][Full Text] [Related]
15. Renal fibrosis: not just PAI-1 in the sky.
Fogo AB
J Clin Invest; 2003 Aug; 112(3):326-8. PubMed ID: 12897200
[TBL] [Abstract][Full Text] [Related]
16. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
18. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
19. [Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology].
Rerolle JP; Vigneau C; Hertig A; Berrou J; Rondeau E
Nephrologie; 2001; 22(1):5-13. PubMed ID: 11280040
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
